Crofelemer for HIV-Associated Diarrhea
Crofelemer is the newer medication for HIV-associated diarrhea that works on chloride channels. This is the only FDA-approved drug specifically indicated for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy 1, 2, 3, 4.
Mechanism of Action
Crofelemer is a plant-derived botanical drug extracted from the red latex sap of the Croton lechleri tree in South America 3. It works by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCCs) in the intestinal lumen 2, 3. This dual inhibition prevents chloride ion secretion into the gastrointestinal tract, which subsequently reduces the efflux of sodium and water, thereby decreasing both the frequency and consistency of diarrhea 3.
Clinical Context
HIV-associated diarrhea remains common despite modern antiretroviral therapy (ART), affecting over half of HIV patients and negatively impacting quality of life and ART adherence 4. The predominant type of diarrhea in HIV patients has secretory characteristics, driven by increased chloride and water secretion into the intestinal lumen 2.
Key Clinical Features
Advantages
- Minimal systemic absorption, resulting in excellent tolerability and few adverse events 2, 3
- No significant drug-drug interactions with ART regimens, unlike many traditional antidiarrheal agents 4
- No abuse liability, unlike opioid-based antidiarrheals 4
- Mechanistically distinct from traditional antimotility agents like loperamide or diphenoxylate
Appropriate Patient Selection
Use crofelemer for:
- Adults with HIV/AIDS on ART experiencing chronic noninfectious diarrhea
- Patients who have completed appropriate diagnostic workup ruling out infectious causes
- Those with secretory-type diarrhea that remains burdensome despite supportive care 1
Important Caveats
- Response is not universal—realistic expectations must be set with patients 1
- Should only be used after infectious causes have been excluded through appropriate stool studies and clinical evaluation
- Not indicated for infectious diarrhea or acute diarrheal episodes
- Efficacy demonstrated specifically in the ADVENT trial for HIV-associated noninfectious diarrhea 2
Practical Prescribing
Crofelemer is administered orally as a tablet formulation. Because it acts locally in the GI tract without systemic absorption, it avoids the complications of systemic antidiarrheal medications that can interfere with ART or cause additional adverse effects 3, 5.